Comstock Inc

During the quarter ended* December 31, 2024*, none of our directors or executive officers adopted, modified or terminated a "Rule10b5-1 trading arrangement" or a "non-Rule10b5-1 trading arrangement" as such terms are defined under Item408 of Regulation S-K.

As previously disclosed, on* December 29, 2021,the Company acquired3,129,081* common shares of its strategic investee, LINICO Corporation, from the former chief executive officer and director of LINICO, Michael Vogel and, at that time, the Company became the owner of90% of the fully-diluted outstanding capital stock of LINICO. Mr. Vogel resigned from LINICO as a member of its board of directors and in all other capacities, effective as of such date. In connection with the acquisition of the LINICO shares, the Company agreed to deliver*$7,258,162* of consideration to Mr. Vogel. As of* February 28, 2025,**$3,218,853* remained outstanding to Mr. Vogel.

On* February**28,* 2025, the Company agreed to make cash payments of*$148,853* and issue common shares of the Company valued at*$2,200,000* to settle all amounts payable to Mr. Vogel in full. If and to the extent that the sale of the shares of the Company's common stock results in net proceeds greater than*$2,200,000,* then Mr. Vogel is required to pay all of such excess proceeds to the Company. If and to the extent that the sale of the Company's common stock results in net proceeds less than*$2,200,000,* then the Company is required to pay cash to Mr. Vogel equal to such shortfall. In* March 2025,the Company plans to issue to Mr. Vogel775,000* shares of its common stock. The Company further agreed to register the Company's common stock for resale by Mr. Vogel under the Securities Act of1933, as amended. The settlement is designed to fully satisfy the existing obligation of over*$3.2* million. The required information is also included in Exhibit10.85 to this report.